The granulocytic inducer C/EBPalpha inactivates the myeloid master regulator PU.1 by Reddy, Venkateshwar
Aus der Medizinischen Klinik und Poliklinik III am Klinikum Großhadern
der Universität München,
Vorstand: Prof. Dr. med. W. Hiddemann
The granulocytic inducer C/EBPa inactivates the
myeloid master regulator PU.1: possible role in lineage
commitment decisions
Dissertation
zum Erwerb des Doktorgrades der Humanbiologie
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität zu München
Vorgelegt von
Venkateshwar A Reddy
Aus Kagaznagar/Indien
2002

Mit Genehmigung der Medizinischen Fakultät
der Universität München
Berichterstatter: Prof. Dr. med. W. Hiddemann
Mitberichterstatter: Prof. Dr. P.B. Becker
Prof. Dr. M. Schliwa
Prof. Dr. C. Haas
Mitbetreuung durch die
promovierten Mitarbeiter: Dr. G. Behre
Dekan: Prof. Dr. med. H.C.K. Peter
Tag der mündlichen Prüfung:  30 Jan 2003

Table of Contents
1. Introduction
1.1  Hematopoiesis 1
1.2  Transcription factors involved in hematopoiesis 2
1.3  Myelopoiesis 5
1.4  Transcription factors 6
1.4.1  PU.1 8
1.4.2  C/EBPa 11
1.4.3  c-Jun 13
1.5  Aim of the study 15
2. Materials
2.1  Reagents 16
2.2  Radioactive substances 17
2.3  Enzymes 17
2.4  Reagent Kits 17
2.5  Standards, Markers and Ladders 18
2.6  Miscellaneous 18
2.7  Biological material 18
2.7.1  Bacteria 18
2.7.2  Mammalian cell lines 18
2.8  Plasmids 19
2.9  Buffers 19
2.10 Growth Media
2.10.1  Bacteria 21
2.10.2  Mammalian cell culture 21
3. Methods
3.1  Transient transfection of adherent eukaryotic cells by LipofectAMINE
22
3.2  Transient transfection of adherent eukaryotic cells by
Effectene 23
3.3  in vitro Transcription and Translation 24
3.4  GST expression of proteins fused to GST 25
3.5  Co-immunoprecipitation 26
3.6  Transductions
3.6.1  Production of retrovirus 26
3.6.2  Transduction of CD34+ cells 27
3.6.3  in vitro liquid culture 27
3.7  Immunolocalization 28
3.8  Real time polymerase chain reaction 28
4  Results
4.1  C/EBPa blocks the transcriptional activity of PU.1
on a minimal TK promoter containing PU.1 DNA
binding sites only 31
4.2  C/EBPa physically interacts with PU.1 35
4.3  C/EBPa inhibits c-Jun co-activation of PU.1 35
4.4  C/EBPa displaces c-Jun from binding to PU.1 in vitro 36
4.5  C/EBPa interacts with PU.1 via its leucine zipper
in the DNA binding domain 40
4.6  C/EBPa does not recruit TSA-sensitive co-repressors
in downregulating PU.1´s transcriptional activity 43
4.7  C/EBPa downregulates PU.1 expression in myeloid
U937 cells 44
4.8  C/EBPa inhibits PU.1 induced dendritic cell
development 44
5  Discussion 51
6  Summary 58
Zusammenfassung 59
7  References 60
11  Introduction
1.1  Hematopoiesis
Hematopoiesis is the process by which mature blood cells of distinct
lineages (e.g. red, white, and lymphoid cells) are produced from
pluripotent hematopoietic stem cells (HSCs); [Scheme 1]1. To sustain
hematopoiesis through an individual’s life time, HSCs must be capable of
(i) maintenance in a non-cycling state, (ii) self-renewal to generate
additional HSCs, and (iii) production of progenitor cells with more limited
developmental potential.
Scheme 1. Hematopoiesis: Differentiation of specific lineages from a common
pluripotent stem cell.
2Progenitors commit to subsets of lineages and ultimately to single
pathways with concomitant expression of the end stage markers
representative of each cell type (Scheme 1). Hematopoiesis is dynamic
both with respect to lineage decisions and location during development.
Within the mammalian embryo the site of hematopoiesis changes from its
initial position in the yolk sac blood glands (primitive hematopoiesis) to
the fetal liver and then to the bone marrow (definitive hematopoiesis).
Although it has been considered axiomatic that HSCs which populate the
adult arise within the yolk sac and migrate to the fetal liver, recent
evidence suggests an intraembryonic origin1.
1.2  Transcription Factors involved in Hematopoiesis
Transcription factors are sequence specific DNA binding proteins
with a variety of functions that include: (i) folding of the DNA molecule,
(ii) the initiation of the DNA replication and (iii) control of gene
transcription2. Transcription factors can be classified according to the three
dimensional structure of their DNA binding motifs. Over 80% of all
transcription factors are characterized by zinc fingers, helix-turn-helix,
helix-loop-helix, leucine zipper and winged-helix motifs2. A number of
transcription factors have been identified that play a role in the
development of erythroid and myeloid lineages3-7. The central role of
transcription factors in these processes has been highlighted by gene
inactivation studies, promoter analysis and ectopic expression of lineage
restricted factors8-10. Rather than being controlled by single master
regulators, lineage-specific gene expression appears to depend on the
combination of factors in overlapping expression domains11. Various
transcription factors involved in hematopoiesis are outlined in Table 1.
3Table 1. Transcription factors involved in hematopoiesis.
Transcription factor Role in Hematopoiesis References
PU.1 essential for the development of myeloid and lymphoid lineages.
The defect in neutrophil differentiation is limited, as incomplete
maturation although delayed is observed in PU.1-/- mice. In
contrast, PU.1 down-regulation is necessary for erythroid
differentiation
12-24
Ets-1 required for NK cell development as well as proper gene
expression control in B and T lymphocytes
25-28
Fli-1 positive regulation of Fli-1 expression is linked to the (i)
induction of proliferation, (ii) inhibition of apoptotic cell death,
and (iii) inhibition of the terminal differentiation program in
erythroid progenitors. In addition Fli-1 is associated with the
induction of the megakaryocytic phenotypic, and maintenance of
normal T cell numbers
29
C/EBPa critical regulator of granulocyte differentiation. C/EBPa-/- mice
show defects in granulocyte and eosinophil development, other
lineages including monocytes/macrophages, red blood cells.
Platelets and lymphoid cells appear to develop normally
30-41
C/EBPb plays an important role in macrophage and B cell development.
In macrophages it functions primarily as a regulator of cytokine
gene expression during inflammatory responses. In addition,
increased expression has been described during neutrophilic
differentiation
42-47{Doppler,
Welte, et al.
1995 702 /id}
C/EBPg involved in B cell development and fetal liver hemopoiesis 48-50
C/EBPd upregulated during myelopoiesis. Similarly to C/EBPb , in
macrophages it functions primarily as a regulator of cytokine
gene expression during inflammatory responses
35
C/EBPe regulator of eosinophil, neutrophil, and macrophage terminal
differentiation. C/EBPe-/- mice show marked defects in
granulocyte and eosinophil  development. No C/EBPe mRNA
was detected in erythroid, megakaryocyte, basophil, B-lymphoid,
or non-hematopoietic cell lines
51-58
AML1/PEBP2b disruption of gene expression studies indicate that
AML1/PEBP2b is necessary for normal development of all
hematopoietic lineages
59;60
PLZF down-regulation of PLZF may be a necessary step for the
differentiation of early bone marrow progenitors
61
MZF-1 important role in the induction of granulopoiesis, possibly linked
to the expansion of myeloid precursors prior to terminal
differentiation
62-64
WT-1 maximal expression found in CD34+/CD33-/Lin- early
progenitor cells down-regulation of WT-1 expression is
necessary for differentiation of myeloid progenitors
65-67
mFOG-1 plays a fundamental role in the development of erythroid and
megakaryocytic lineages
68-70
HOXA10 its expression is associated with amplification of early
hematopoietic precursors and megakaryocytes. Down-regulation
of HOXA10 is important for myeloid and B-lymphoid
differentiation
71-73
HOXA5 several lines of evidence indicate that HOXA5 gene expression
positively regulates granulocytic/monocytic differentiation,
whereas its down-regulation is necessary for progression of
erythropoiesis
74
4positively regulates granulocytic/monocytic differentiation,
whereas its down-regulation is necessary for progression of
erythropoiesis
HOXA9 important role in the development of myeloid, erythroid, and B
cell progenitors
75;76
HOXB3 down regulation of HOXB3 expression, compared to
CD34+/Lin- bone marrow progenitors, is necessary for normal
lymphoid (B and T cell) development. In contrast, HOXB3 over-
expression preferentially upregulates myeloid development.
77
HOXB4 key role in the expansion of primitive bone marrow hemapoietic
cells
78;79
HOXB8 role in positive regulation of macrophage development, and
negative regulation of granulocytic development
77
other HOX genes several other genes of the HOXB (B2, B6-B9), and HOXC (C6,
C8), appear to play a role in the regulatory development of
erythropoiesis
80
EGR-1 selective upregulation of EGR-1 gene expression is associated
with differentiation along the macrophage lineage, where
maximal expression is reached in mature cells. In contrast, EGR-
1 negatively regulates granulocytic lineage development
81
c-Myb expression of c-Myb is crucial for the survival and proliferation
of early hemapoietic progenitors. In contrast, c-Myb down-
regulation is required for terminal cell differentiation.
82-84
c-Myc expression levels are high in proliferating myeloid progenitors
and its down-regulation activates the terminal differentiation
program. In contrast, forced c-Myc expression negatively
regulates the terminal differentiation program.
85;86
AP-1 (Jun/Fos) several lines of evidence suggest a role for AP-1 in the
modulation of apoptotic pathways and the functional
development of several hemopoietic lineages including the
monocyte/macrophage, granulocyte, megakaryocyte, monocyte
and erythroid lineages
87;88
GATA GATA-1 and GATA-3 play key roles in the positive regulation
of erythroid and megakaryocyte development, as well as the
negative regulation of myeloid development. In the presence of
C/EBPa , however GATA-1 induces eosinophil lineage
development. GATA-3 expression is restricted to T- and NK-
cells, and has been found to be required for T cell lineage
commitment and differentiation
89;90
STAT1 central role in differentiation along the mononuclear phagocyte
lineage, through the induction of functional genes, such as
ICAM-1 and FcgR1
91
STAT3 essential for gp130-mediated induction of proliferation,
differentiation and survival signals in response to IL-6 signalling
92
STAT4 STAT4 expression, associated with early myeloid progenitors, is
down regulated during erythroid and granulocytic differentiation
93
SCL absolutely required for the development of embryonic, fetal and
adult hemopoietic stem cells. SCL modulates cellular
differentiation both positively in erythroid, myeloid, and
megakaryocytic lineages and negatively in macrophage lineage
94;95
IRF-1 modulates gene expression in developing thymocytes, required
for lineage commitment and selection of CD8+ thymocytes
96
ICSBP positive role in differentiation of bipotential myeloid progenitors
cells towards the macrophage lineage, as well as repression of
specific genes associated with terminal granulocytic
differentiation
97;98
5cells towards the macrophage lineage, as well as repression of
specific genes associated with terminal granulocytic
differentiation
MafB specific-upregulation of MafB expression plays an important role
in the induction of the mononuclear phagocyte differentiation
program and repression of erythroid specific gene expression in
myeloid cells
99;100
E2A the earliest appearing gene thought to be responsible for
commitment to the B cell lineage
101;102
BSAP/Pax5A expressed immediately after commitment to the B cell lineage in
the bone marrow, BSAP/Pax5A continues to be expressed
throughout B cell development except in plasma cells, where it
maintains commitment to the B cell lineage
102
EBF function in the development of B cell progenitors following
commitment to the B cell lineage
103
: Adapted from Barred et al., Developmental and comparative immunology, 2001
1.3  Myelopoiesis
The coordinated production of all blood cells from a common stem
cell is a highly regulated process involving successive stages of
commitment and differentiation. The myelopoietic system includes the
hematopoietic cells derived from a common hematopoietic stem cell that
includes erythroid, granulocytic, monocytic and megakaryocytic lineages.
Myeloid cell differentiation (Scheme 2) has been investigated on many
levels, from the cytokine signals required by each cell lineage to the
Scheme 2. Myeloid cell differentiation from a pluripotent myeloid progenitor cell into
a single lineage monocyte or granulocyte.
6scheduled expression of distinctive myeloid cell-specific genes and the
programmed appearance of characteristic cell surface markers. By analogy
to progress in other developmental systems, such as muscle and liver cell
differentiation, it should be possible to establish a hierarchy of
differentiation signals and transcriptional processes for developing
myeloid cells. An attractive emerging concept implicates the programmed
regulation of key transcription factors at different stages of development,
coordinated by receptor-mediated signals from myeloid colony-stimulating
factors104. The development of distinct lineages like monocytes-
/macrophages, granulocytes and megakaryocytes from hematopoietic
precursor cells is controlled by a myriad of transcription factors which
regulate the expression of essential genes, including those encoding
growth factors and their receptors, enzymes, adhesion molecules, and
transcription factors themselves105. The various transcription factors which
have been implicated in myelopoiesis are PU.1, C/EBP members (a, b, d
and g), CBF, c-Myb, Ets, HOX, MZF-1, AML1/CBFb, AP-1 members etc.
Various growth factors are responsible for myelopoiesis, the most
important ones are G-CSF (granulocyte-colony stimulating factor), M-CSF
(macrophage-colony stimulating factor) and GM-CSF (granulocyte-
macrophage-colony stimulating factor).
1.4  Transcription factors PU.1, C/EBPa and c-Jun
Hematopoietic differentiation program involves activation of
transcription factors like PU.1, C/EBPa, GATA-1 and c-Jun, followed by
increased expression of colony stimulating growth factor receptors, and
maturation of the committed cells induced by transcription factors and
cytokines (Scheme 3).
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81.4.1  PU.1
PU.1 is a member of the Ets transcription family12. All Ets factors
contain a characteristic DNA binding domain of approximately 80 amino
acids18,25,106. PU.1 and the related Ets family member Spi-B form a distinct
subfamily within the larger group of Ets proteins, with very distinct
structure, patterns of expression, binding specificity, and functions that are
non-overlapping with other members of the Ets family. The PU.1 protein
consists of 272 amino acids,
with the DNA binding
domain located in the
carboxyl terminal part of
the protein, whereas the
amino terminus contains an
activation domain that has
been implicated in inter-
ac t ions  wi th  o ther
regulatory proteins107-109.
The structure of the DNA
binding domain has been
recently determined and
demonstrates a winged helix-turn-helix motif110 (Figure 1).
PU.1 shows specific patterns of hematopoietic expression. PU.1 is
expressed at highest levels in myeloid and B cells, but not in T cells20,12.
During hematopoietic development, PU.1 mRNA is expressed at low
levels in murine ES cells and human CD34+ stem cells and is specifically
upregulated during myeloid differentiation. The timing of this upregulation
coincides with the first detection of early myeloid maturation, suggesting
that this increase in expression may be an important process in myeloid
development, and inhibition of PU.1 function at this juncture can block
myeloid progenitor formation111. Studies in both primary CD34+ cells and
human leukemic cell line models suggest that PU.1 mRNA and DNA
binding activity do not increase further with subsequent myeloid
Figure 1. Crystal structure of PU.1 DNA
binding domain, bound to DNA
b4
b3
9maturation from the promyelocytic to more mature stages111,20, but these
studies do not preclude the possibility that the high levels of mRNA
observed in human monocytes is a result of subsequent final maturation
and/or activation. These expression studies suggest that regulation of PU.1
mRNA may play a significant role in the commitment of early
multipotential progenitors to the myeloid lineages, as well as in the further
differentiation and maturation of these cells.
Using retroviral transduction of PU.1 complementary DNA into
mutant hematopoietic progenitors, it has been demonstrated that differing
concentrations of the protein regulate the development of B lymphocytes
as compared to macrophages. A low concentration of PU. 1 protein
induces the B cell fate, whereas a high concentration promotes
macrophage differentiation and blocks B cell development. Conversely, a
transcriptionally weakened mutant protein (in the transactivation domain)
preferentially induces B cell generation112.
The important functional sites identified so far in the PU.1
promoter, an octamer site at bp -54, an Sp1 site at bp -39, and a site for
PU.1 itself at bp +20, are conserved in both human and mouse113. In B
cells, the octamer site plays a major role in PU.1 expression114. These
findings suggested that PU.1 is auto-regulatory in its expression. PU.1,
like other Ets factors, was first noted to bind to a sequence characterized
by a purine-rich core (GGAA), hence its name25. However, the DNA
binding specificity of PU.1 appears to be quite distinct from that of other
Ets factors.
PU.1, like other Ets proteins, interacts with other transcriptional
regulators. The various factors known, so far, to interact are PU.1
interacting protein (Pip), NF-IL6 (C/EBPd), c-Jun, TBP, RB, GATA1 and
CBP115-117,107.
Ets family members have been shown to play an important role in
several signal transduction pathways118-121. PU.1 is phosphorylated in vitro
by casein kinase II and JNK kinase, but not by ERK1 (MAP) kinase. A
recent study has shown that lipopolysaccharides (LPS) can activate casein
10
kinase II and phosphorylation of PU.1 in LPS-stimulated macrophage
lines122. The LPS stimulation of PU.1 transactivation of a reporter
construct was abolished by a serine to alanine mutation of residue 148,
suggesting that stimulation of macrophages with LPS leads to increased
phosphorylation and activity of PU.1.
Several groups have addressed the function of PU.1 on murine
development using targeted disruption of the PU.1 gene17,24. Singh et al.,
have reported that PU.1-/- embryos die in utero, usually at day E16123.
These animals demonstrated variable anemia, but no production of any
type of white blood cells, including monocytes, neutrophils, and B cells, as
might be expected based on the expression of PU.1 and its known target
genes. The concomitant failure to produce T cells in the (-/-) animals was
surprising, given that PU.1 has not been known to be expressed in this
lineage. These studies suggested that the defect was either due to a block
of a very early multi-lineage progenitor cell or that T-cell development is
dependent on the presence of macrophages and/or B cells. The PU.1
knockout mice Maki et al., yielded a phenotype with some distinct
differences124. The PU.1-/- mice in this case were viable at birth and could
be kept alive for days by housing them in a sterile environment with the
administration of antibiotics. These animals also lacked monocytes and
mature B cells, but were capable of producing B-cell progenitors. Several
days after birth, T cells and cells resembling neutrophils were detected in
the peripheral blood. In this case, the findings suggested a role for PU.1 in
B-cell and monocytic development, which is more in keeping with its
known pattern of expression and its known gene targets. Although
neutrophilic cells were observed, they were Mac-1 negative and reduced in
number, suggesting that targeting PU.1 results in a partial defect in
neutrophil development. The former knockout model suggests that PU.1
plays an important role in multipotential cells; the latter knockout model
suggests a more limited role in B-cell and myeloid development.
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In vitro differentiation of PU.1-/- embryonic stem cells does not
produce macrophages and points to the M-CSF receptor as a major target
of PU.1 in understanding its effect on myeloid differentiation125,126.
1.4.2  C/EBPa
CCAAT/enhancer binding protein (C/EBP) transcription factors
belong to the bZIP family of proteins, which contain a basic domain
involved in DNA binding, and a leucine zipper motif involved in homo
and heterodimerization. C/EBPa  the founding member of the C/EBP
transcription factors is most abundantly expressed in adipose tissue,
placenta, liver and is also detected in a variety of other organs such as
lung, kidney, small intestine, brain and hematopoietic cells127. C/EBPa has
been shown to play a significant role in adipocyte differentiation,
regulation of both liver and adipocyte specific genes, energy metabolism
and cell proliferation128,129. C/EBPa is also expressed in early myeloid
cells130,61.
A number of granulocytic specific genes including the granulocyte-
colony stimulating factor (G-CSF) receptor, neutrophil elastase, and
myeloperoxidase genes have been shown to be regulated by
C/EBPa34,35,131. Inhibition of C/EBPa  blocks differentiation and
expression of C/EBPa induced differentiation.
The C/EBPa promoter is autoregulatory. Murine C/EBPa promoter
has a binding site for C/EBPa132. The human C/EBPa promoter does not
conserve the C/EBPa binding site found in the murine promoter, and the
autoregulation is indirect and mediated by the action of C/EBPa on a
helix-loop-helix protein, the upstream stimulatory factor (USF)133.
Northern blot analysis of human CD34+ cells shows that C/EBPa
expression is maintained during granulocytic differentiation but is
markedly downregulated with monocytic or erythroid differentiation. In
addition mature peripheral blood neutrophils show high levels of C/EBPa
12
mRNA, which is completely undetectable in adherent peripheral blood
monocytes.
As noted above, C/EBPa was the first protein noted to have the
leucine zipper motif134. The leucine zipper is a protein motif structure
common to a new class of DNA binding proteins and is directly involved
in homodimerization and heterodimerization. C/EBPa, C/EBPb , and
C/EBPd are very similar in their C-terminal basic region and leucine
zipper domains and diverge in the N-terminal transactivation domain135-138.
In addition to other members of the C/EBP family, the C/EBP
proteins can interact with a number of transcription factors, including
NF-kB and Rel proteins139,140, members of the CREB/ATF family141,142,
Sp1143, RB and members of the fos/jun zipper family144. The amino
terminal region of C/EBPa has been shown to physically interact with
TBP145. As noted above, C/EBPd has been shown to interact with PU.1146,
and PU.1 can physically interact with C/EBPb  as well (P. Auron
unpublished observation).
C/EBPa knockout mice show an interesting phenotype: homo
zygous mice die within the first few hours after birth of impaired glucose
metabolism; their viability can be extended to about 1 day with injections
of glucose. Analysis of the hematopoietic system of the knockout
embryonic and newborn mice demonstrated a significant defect in
production of granulocytic cells147. Newborn knockout (-/-) animals do not
produce any mature neutrophils, which comprise 90% of the peripheral
white blood cells of newborn heterozygote (+/-) or wild-type (+/+) mice.
Eosinophils are also not observed, but all of the other lineages, including
peripheral blood monocytes and peritoneal macrophages, red blood cells,
platelets, and lymphoid cells, appear quantitatively unaffected. Myeloid
markers (Mac-1 and Gr-1) were greatly reduced, with normal B- and T-
cell subsets. Expression of the G-CSF receptor mRNA was profoundly and
selectively reduced, whereas that of M-CSF receptor and GM-CSF
receptor a, bc, and bIL3 were all comparable to wild-type.
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These findings suggested that much of the phenotype may be due to
decreased or absent G-CSF signaling due to markedly reduced receptor
levels. However, G-CSF receptor knockout animals produce mature
granulocytes, in contrast to C/EBPa knockouts, strongly suggesting that
there must be important C/EBPa target genes in myeloid progenitors in
addition to the G-CSF receptor148.
In summary, the C/EBP proteins are differentially expressed and can
interact with themselves and other transcription factors. These studies
showed that C/EBPb (and C/EBPd) may be involved in activation of
cytokines in mature cells, whereas C/EBPa  has a major role in
granulocytic maturation through regulation of the G-CSF receptor and
other as yet not identified target genes.
1.4.3  c-Jun
AP-1 transcription factors play a major role in myelopoiesis. Proto-
oncogenes c-Jun, junB, and junD are stably induced suggesting their role
in the initiation, progression, and maintenance of the myelopoietic
differentiation program.
c-Jun belongs to the bZIP group of DNA binding proteins and is a
component of the AP-1 transcription factor complex149. c-Jun forms
homodimers or can heterodimerize with other Jun family members or with
other bZIP proteins including members of the fos and ATF/cAMP
response element-binding protein (CREB) families88.
AP-1 members have been shown to be involved in many cellular
processes including proliferation, apoptosis and stress responses. In
particular, there is evidence that c-Jun plays a role in monocytic
differentiation. c-Jun mRNA is upregulated upon monocytic
differentiation of bipotential myeloid cell lines. While stable expression of
c-Jun into myeloid cell lines results in partial differentiation150,151. For
several years it was unclear if c-Jun plays any role in the upregulation of
M-CSF receptor (M-CSFr) expression, though there are AP-1 binding sites
14
in M-CSFr promoter. TPA treatment of U937 cells induces c-Jun
expression showing the role of c-Jun in myeloid differentiation.
Lately it was shown that c-Jun enhances the ability of PU.1 to
transactivate the human monocyte-specific M-CSF receptor promoter, and
it was also shown that c-Jun is a JNK independent co-activator of the PU.1
transcription factor117. C/EBPa kockout mice show high level of c-Jun
expression. This points to the fact that C/EBPa might down-regulate c-Jun
expression to drive the cells to granulocytic lineage.
15
1.5  Aim of the Study
The aim of this study is to elucidate the molecular mechanisms that
decide whether a common precursor will develop and differentiate along
the granulocyte or monocyte lineage.
In particular we set out to examine how the transcription factors
PU.1 and C/EBPa are regulating the development of pluripotent myeloid
progenitor cells.
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2  Materials
2.1  Reagents
Acrylamide-Bisacrylamide Biorad GmbH, Munich, Germany
Agar Life Technologies, Paisley, Scotland
Agarose Life Technologies, Paisley, Scotland
APS Fluka, Buchs, Switzerland
Acetic acid Merck, Darmstadt, Germany
Bromphenolblue Sigma, St. Louis, U.S.A
Coomassie-Blue R-250 Life Technologies, Paisley, Scotland
DMEM PAN Biotech, Aidenbach, Germany
DTT Sigma, St. Louis, U.S.A
Ethanol Merck, Darmstadt, Germany
Ethidium bromide Sigma, St. Louis, U.S.A
Fetal bovine serum Life Technologies, Paisley, Scotland
Formaldehyde Sigma, St. Louis, U.S.A
Formamide Sigma, St. Louis, U.S.A
l-Glutamine Life Technologies, Paisley, Scotland
Glycerin Merck, Darmstadt, Germany
HEPES Sigma, St. Louis, U.S.A
IPTG Sigma, St. Louis, U.S.A
Isopropanol Merck, Darmstadt, Germany
b-Mercaptoethanol Sigma, St. Louis, U.S.A
Methanol Merck, Darmstadt, Germany
MOPS Sigma, St. Louis, U.S.A
PBS PAN Biotech, Aidenbach, Germany
Penicillin/Streptomycin Life Technologies, Paisley, Scotland
RPMI PAN Biotech, Aidenbach, Germany
Sodium chloride Merck, Darmstadt, Germany
SDS Serva, Heidelberg, Germany
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TEMED Biorad, Munich, Germany
Tris-HCl Merck, Darmstadt, Germany
Trichostatin A Sigma, St. Louis, U.S.A
Trypsin/EDTA PAN Biotech, Aidenbach, Germany
Xylencyanol Sigma, St. Louis, U.S.A
Zinc sulfate Sigma, St. Louis, U.S.A
2.2  Radioactive Substances
a-[32P]-dCTP Amersham, Braunschweig, Germany
L-35S-Methionine Amersham, Braunschweig, Germany
2.3  Enzymes
Restriction enzymes New England Bio-labs,
   Frankfurt, Germany
GIBCOBRL, Paisley, Scotland
RNasein Promega, Mannheim, Germany
2.4  Reagent Kits
MACS (CD34 positive Miltenyi Biotech, Gladbach,
cell isolation kit) Germany
Lymphoprep Nycomed, Oslo, Norway
Plasmid Isolation kit Qiagen, Hilden, Germany
Glutathione Sepharose Pharmacia, Freiburg, Germany
TNT-Reticulocyte- Promega, Mannheim, Germany
lysate-system
LipofectAMINE plus GIBCOBRL, Paisley, Scotland
Effectene Qiagen, Hilden, Germany
Biorad-protein estimation kit Biorad, Munich, Germany
Luciferase assay kit Promega, Mannheim, Germany
Fast Start DNA SYBR Roche Diagnostics, Mannheim,
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green I-Kit Germany
2.5  Standards, Markers and Ladders
Protein marker Biorad, Munich, Germany
DNA marker NEB, Frankfurt, Germany
1-kb ladder NEB, Frankfurt, Germany
100bp ladder NEB, Frankfurt, Germany
2.6  Miscellaneous
Blotting paper Schleicher and Schüll, Stuttgart, Germany
Membrane (Nitrocellulose) Amersham, Millipore
Pipet tips Star Labs (K&K labordarf), Munich,
Germany
Plastic material (tubes etc) Eppendorf, Greiner, Falcon, Munich,
Germany
Quartz Cuvette Hellma
Reaction tubes Eppendorf
X-ray film Kodak (Biomax)
Filters Millipore
Ultra centrifuge tubes Beckman
Cell culture material CoStar, Cellstar, Nunc and Greiner
2.7  Biological material
2.7.1  Bacteria
Escherichia coli DH5 alpha
Escherichia coli BL-21
2.7.2  Mammalian cell lines
293T (human kidney fibroblasts)
F9 (mouse embryonal carcinoma)
19
CV1
U937 (human myeloid cell line)
U937 (Zn2+ inducible C/EBPa)
2.8  Plasmids
p(PU.1)4TK
p(mut.PU.1)4TK
p(C/EBP)2TK
pTK
pGL2
pXP2
pRL-null
pCMV5
pECE PU.1
pcDNA3.1 C/EBPa
pMSCV C/EBPa mBR
pMSCV C/EBPa DLZ
pMSCV C/EBPa (rat)
pGEX2TK-PU.1
pGEX-C/EBPa DNA binding domain
pS3H-c-Jun
2.9  Buffers
Buffers provided with the kits were used in the case of Plasmid isolation,
protein expression, RNA isolation, and Real time Polymerase chain
reaction. The other buffers used are listed below.
Binding buffer (GST-Pull down)
 (NETN) 150 mM NaCl2
(with protease inhibitors) 0.5 mM EDTA
50 mM Tris
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1% NP40
5% Glycerol
Electrophoresis buffer (SDS-PAGE) 25 mM Tris, pH 8.3
250 mM Glycine
0.1 % SDS
Destaining solution 30 % Methanol
10 % Acetic acid
Staining solution 30 % Methanol
10 % Acetic acid
0.25 % Coomassie-Blue R-250
Electrophoresis buffer (Tris-Glycine) 250 mM Tris
(pH 8.3) 1.9 M Glycine
10mM EDTA
Tris-Borate buffer 0.89 M Tris
0.89 M Boric acid
0.5 M EDTA
EMSA binding buffer 20 mM HEPES
60 mM KCl
24 % Glycerol
0.5 mM DTT
0.4 mM PMSF
10 mM MgCl2
0.2 mM EDTA
Agarose gel electrophoresis loading 40 % Saccharose
dye (6x)
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0.25 %Bromophenolblue
0.25 % Xylenecyanol
SDS-PAGE gel loading dye (2x) 125 mM Tris/HCl,
pH (6.8) 4 % SDS
10 % b-Mercaptoethanol
30 % Glycerol
0.004 % Bromophenolblue
Western Stripping solution 0.1 M b-Mercaptoethanol
2 % SDS
1M Tris (pH 6.8)
TE buffer 50 mM Tris/HCl, pH 8.0
1 mM EDTA
Trypsin/EDTA solution 0.05 % Trypsin
0.02 % EDTA
in PBS
2.10  Growth media
2.10.1  Bacteria
LB (luria bertani) Medium lb medium with respective
antibiotics
2.10.11  Mammalian cell culture
293T, CV1 DMEM
10 % FBS
1 % L-Glutamine
1% Penicillin-Streptamycin
F9 DMEM (4,5 g/l Glucose)
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10 % FBS
1 % L-Glutamine
1% Penicillin-Streptamycin
U937 RPMI
10 % FBS
1 % L-Glutamine
1% Penicillin-Streptamycin
3  Methods
3.1  Transient transfection of adherent eukaryotic cells by
LipofectAMINE
The day before transfection, cells were trypsinized, counted and
plated so that they were 50-80% confluent the day of transfection.
Antibiotics were avoided at the day of transfection and during plating to
help cell growth and increased transfection efficiency. DNA was pre-
complexed to PLUS reagent: DNA was diluted in serum free medium.
PLUS reagent was mixed before adding it to the diluted medium. The
complete mixture was incubated at room temperature for 15 min.
LipofectAMINE reagent was diluted and mixed in a serum free
medium in a second tube. Pre-complexed DNA and diluted
LipofectAMINE reagent were mixed and incubated for 15 min at room
temperature. During this incubation period, cells were rinsed with serum
free medium to enable higher transfection activity. DNA-PLUS-
LipofectAMINE reagent complexes were added to each well containing
fresh medium. The complexes were gently mixed with the medium;
incubated at 37°C at 5% CO2 for 3hrs. After 3hrs of incubation medium
volume was increased to normal volume by adding medium containing
20% fetal bovine serum.
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24hrs after the transfection assay cell extracts were obtained for reporter
gene activity.
Amounts of reagents used for transfection:
DNA (mg)
PLUS reagent
(ml)
LipofectAMINE
reagent (ml)
Transfection
volume (ml)
24 well 0.4 4 1   0.25
12 well 0.7 5 2 0.5
6 well 1 6 4 1.0
60 mm 2 8 12 2.5
100 mm 4 20 30 6.5
Cell number: 1 x 104 – 24 well
 1 x 105 – 6 well
 1 x 105 – 60 mm
 2 x 105 – 100 mm
3.2  Transient transfection of eukaryotic cells (adherent and
suspension) by Effectene
Cells are plated to the density stated above the day before trans
fection. On the day of tranfection DNA was diluted in DNA condensation
buffer, buffer EC, to a total volume of 150 ml. 8 ml of enhancer were added
and vortexed for 1s. The complex is incubated at room temperature for 2-5
min and spun down shortly. 25 ml of effectene transfection reagent was
added to the DNA-enhancer mixture. The complex was vortexed for 10s,
and incubated at room temperature for 5-10 min to allow transfection-
complex formation. During this period the growth medium was gently
aspirated from the plate and cells were washed with 4 ml of PBS. 4 ml of
fresh medium with FBS and antibiotics was added (RPMI for suspension
cells and DMEM for adherent cells). Fresh medium was added to the
transfection complexes and added on to the cells. The dish was gently
24
swirled to ensure the uniform distribution of the transfection complexes.
Cells were incubated in normal conditions for an appropriate time for
expression of the transfected gene.
Amount of reagents used for transfection:
Culture
format
DNA
(mg)
Enhanc
er
(ml)
Final volume of
DNA in buffer
EC (ml)
Effectene
Reagent
(ml)
Volume of
medium to
cells (ml)
Volume of
Medium to
complexes  (ml)
24 – well 0.2 1.6 60 5 350 350
6 – well 0.4 3.2 100 10 1600 600
60 mm 1.0 8.0 150 25 4000 1000
100 mm 2.0 16.0 300 60 7000 3000
Cell number:
24-well  2-8 x 104
6-well  0.9-4 x 105
60 mm dish  2-8 x 105
100 mm dish  0.5-2.5 x 106
3.3 in vitro Transcription
PU.1, C/EBPa and c-Jun were in vitro transcribed and translated,
using the TNT Reticulocyte Lysate System and with labeled [35S]
methionine. For a 50 ml reaction the following volumes were used:
TNT rabbit reticulocyte lysate 50 ml
TNT reaction buffer   2 ml
Enzyme(c-Jun SP6; C/EBPa T7; PU.1 T3)   1 ml
Amino acids (-methionine)   1 ml
35S - methioine   4 ml
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RNAsin   1 ml
plasmid DNA (~ 1mg)
dH2O
to make the final volume to 50 ml
The reagents were mixed and incubated at 30°C for 90 minutes.
3.4  GST expression of proteins fused to GST
[e.g., PU.1-GST, C/EBPa-GST, PU.1 (b3-b4)-GST, DNA binding domain
C/EBPa-GST]
DH5a bacteria carrying the PU.1-GST fusion constructs, and the
BL-21 cells carrying the C/EBPa-GST constructs were grown in Luria
bertani with the respective antibiotics. Starter cultures of 10 ml were
grown overnight and transferred to 100 ml fresh media and the bacteria
was grown at 37°C till the OD600 was 0.6. The culture was then induced
with 0.5 mM isopropyl b-D-thiogalactoside (IPTG) for 2-3hrs at 30°C.
The bacteria were pelleted at 4,000 rpm. The bacteria were suspended and
lysed in NETN buffer with the respective protease inhibitors. The cell
membrane was opened by sonication (duty cycles 40-50 / amplitude 20%,
5 times with interval of 5 min). The lysates were spun down for 30 min at
4°C at maximum speed (14,000 rpm). The supernatant was saved and
preserved at -20°C.
Meanwhile Glutathione sepharose beads were washed with PBS two
times and spun at 2.000 rpm at 4°C for 5 min. Finally the beads were
suspended in NETN buffer with low salt concentration (100mM NaCl).
The supernant was bound to the glutathione sepharose beads at 4°C over
night on a rocking platform. The protein bound beads were then washed 4
times with the wash buffer to eliminate non-specifically bound protein.
The protein bound beads were centrifuged at 2,000 rpm at 4°C for 5 min
everytime. The purified protein recovery was roughly estimated by SDS
polyacrylamide gel electrophoresis, with known concentration of BSA
loaded in the same gel.
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3.5  Co-immunoprecipitation
293T cells were transfected at a density of 1x106 in 100 mm plates.
The cells were transfected with Effectene with respective DNA´s (eg.,
PU.1, C/EBPa, C/EBPa mBR and C/EBPa  DLZ) and the empty vector
pCMV5 in different combinations. 24 hours post transfection cells were
scrapped with a cell scraper. Cells were washed with PBS and then
subjected to lysis for whole cell lysate with Co-IP buffer (50 mM Tris pH
7.5, 150 mM NaCl, 1mM EDTA, 5 % Glycerol, 1 % NP40 and protease
inhibitors).
Sample preparation – lysates were diluted in 1 ml buffer, the cells were
mixed well, and kept on ice for 30 min. It was vortexed every 10 minutes.
The lysates were spun at 14,000 rpm for 30 min at 4°C. The supernatant
were preserved at -20°C.
Preparation of Protein A sepharose beads – 50 ml of 75 % protein A beads
were diluted in 5 ml of PBS. Spun at 300 rpm for 5 min. The buffer was
removed and fresh buffer added. Respective antibodies were added to the
protein A sepharose beads. The antibody bound to the beads was
recovered after washing with the wash buffer.
Immunoprecipitation & western blot for coimmunoprecipitation– The
lysate is added to the protein A agarose beads bound to the antibody and
incubated at 4°C rotating for 120 min. Western blot analysis was
performed to find the proteins interacting with immunoprecipitated
protein.
3.6  Transductions
3.6.1  Production of retrovirus
Mouse PU.1 cDNA followed by IRES nerve growth factor receptor
truncated in the cytoplasmic domain (tNGFR) and human C/EBPa cDNA
followed by IRES EGFP were subcloned into a retroviral vector, pMSCV,
with an LTR derived from MSCV (pMSCV-PU.1-IRES-tNGFR and
pMSCV- C/EBPa-IRES-EGFP, respectively). To produce virus, plasmid
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DNA was transfected into 293gp cells (293 cells containing the gag and
pol genes but lacking an envelope gene) along with 10A1 env expression
plasmid (pCL-10A1) by CaPO4
- co-precipitation and supernatant from the
transfected cells was collected to transduce cells.
3.6.2  Transduction of CD34+ cells
 Human umbilical cord blood samples were obtained, with informed
consent of the parents, from placentas of full-term normal newborn
infants. After isolation of mononuclear cells from cord blood by density
gradient centrifugation, CD34+ cells were obtained using magnetic bead
separation according to the manufacturer’s instructions. CD34+ cells were
prestimulated in IMDM supplemented with 10% FBS, 50 ng/ml stem cell
factor, 50 ng/ml thrombopoietin (kindly provided by KIRIN, Tokyo,
Japan), 50 ng/ml IL-6 (Peprotech, Rocky Hill, NJ), and 50 ng/ml Flt-3L
(Peprotech) for 20hrs. After replating onto recombinant fibronectin
fragment coated culture dishes (Takara Shuzo, Otsu, Japan) containing
virus supernatant and 5 mg/ml protamine sulfate (Sigma), cells were
centrifuged at 1,000x g for 30 min. Transduction was repeated with fresh
virus supernatant every 12hrs three times. At 60hr after the first
transduction, NGFR- and/or EGFP-positive cells were selected by cell
sorting on a FACS Vantage (Becton Dickinson, San Jose, CA) and
subjected to subsequent analyses. To detect the expression of tNGFR on
the cell surface, cells were stained with mouse anti-human NGFR
(CHEMICON, Temecula, CA) followed by phycoerythrin (PE)-conjugated
rabbit anti-mouse immunoglobulins (DAKO A/S, Glostrup, Denmark).
3.6.3  In vitro liquid culture
CD34+ cells transduced with either PU.1 or C/EBPa retroviruses, or
co-transduced with PU.1 and C/EBPa retrovirus were cultured in IMDM
supplemented with 10% heat-inactivated FBS and 50 ng/ml stem cell
factor, 50 ng/ml G-CSF, 50 ng/ml GM-CSF, and 50 ng/ml IL-3 (KIRIN) at
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37°C in 5% CO2. On day 10 of culture, expression of cell surface antigens
were analyzed on a FACS Vantage using PE-conjugated anti-human CD1a
(Immunotech, Marseille, France). Cells were also cytocentrifuged onto
glass slides and were stained with May-Gruenwald’s solution (Merck,
Darmstadt, Germany) followed by Giemsa’s solution (Kanto Chemical
Co., Inc. Tokyo, Japan).
3.7  Immunolocalization
U937 cells were cytocentrifuged onto glass slides, cells were fixed
with ice-cold acetone for 2 min, dried and rehydrated in PBS. Slides were
blocked in 10% FCS for 30 min at RT, washed with PBS and incubated
overnight at 4oC with primary antibodies. Cytospins were washed with
PBS and then incubated with secondary antibodies Texas red and Cy3 for
45 min. Slides were washed with PBS and mounted with anti-fade
solution.
3.8  Real time polymerase chain reaction
Quantitative Realtime PCR using the LightCyclerTM-Systems (LC)
offers real time monitoring of PCR product formation. PCR cycles, in
which the PCR product increases logarithmically can be identified and the
starting concentration of the target DNA determined. We used the Fast
Start DNA SYBR Green I-Kit (Roche Diagnostics, Mannheim, Germany)
as a mastermix. SYBR Green I Dye is a fluorescence dye, which binds to
double-stranded DNA. The fluorescence signal was recorded at the end of
each elongation phase and the increasing amounts of PCR product can be
monitored from cycle to cycle. We quantified the expression of the
transcription factor PU.1 in U937 cell line with zinc inducible expression
of C/EBPa. For each sample, we also measured the concentration of the
mRNA of the housekeeping gene G6PD to control for variances in the
cDNA synthesis step. Thus, we performed relative quantification of the
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target gene by comparing it to the concentration of the housekeeping gene
G6PD. The concentrations of the target genes and the housekeeping gene
G6PD were calculated by reference to a standard curve. For that we
serially diluted a G6PD plasmid: pGdBBX, kindly provided by A.
Hochhaus32, to 10,000fg, 1,000fg and 100fg. We formed ratios between
the target gene and the housekeeping gene G6PD (target gene/ G6PD) and
compared them to each other. Downregulation of PU.1 upon C/EBPa
induction or the downregulation of PU.1 upon zinc addition in empty
vector carrying U937 cells were shown as PU.1/G6PD ratio values directly
compared to each other at various time points from 0hrs to 8hrs after
C/EBPa induction.
PCR for PU.1 was performed according to the manufacturer’s
protocol from Search LC-Heidelberg, Germany. Amplification occurred in
a three-step cycle procedure initiated by a 10 min denaturation at 95°C to
activate the polymerase: 95°C, 0s; annealing 68°C, 10s; and extension
72°C, 16s for 35 cycles. Fluorescence of SYBR Green I was measured
after each extension step at 530 nm.
PCR for G6PD was performed using 2ml mastermix (Light Cycler
FastStart DNA Master SYBR Green I, Roche Diagnostics, Mannheim,
Germany), 2ml cDNA (from U937 Zn C/EBPa and U937 pPC18) 4mM
MgCl2, .75mM of each primer, and water to a final volume of 20ml.
Amplification occurred in a three-step cycle procedure initiated by a 10
min denaturation at 95°C to activate the polymerase: 95°C, 0s; annealing
64°C, 10s; and extension 72°C, 25s for 35 cycles. Fluorescence of SYBR
Green I was measured after each extension step at 530 nm. For
amplification of G6PD, primers were used according to Emig et al32. The
final PCR cycle is followed by a melting curve analysis to confirm the
PCR product identity and differentiate it from non-specific, e.g. primer-
dimer products. For that, the products were denatured at 95°C, annealed at
58°C, and then slowly heated up to 95°C with fluorescence measurement
at 0.2°C increments. Amplification products performed in the Light Cycler
were checked by electrophoresis on 1% ethidium bromide stained agarose
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gels. The estimated size of the amplified fragments matched the calculated
size: for PU.1: 150 bp and G6PD: 343bp.
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4  Results
4.1  C/EBPa blocks the transcriptional activity of PU.1 on a
minimal TK promoter containing PU.1 DNA binding sites
only
Within the myeloid compartment, the same committed precursor
can give rise to monocytic or granulocytic cells. This raises a question:
What are the molecular mechanisms that dictate the fate of the common
precursor to one or the other of these two diverse myeloid lineages? Since
PU.1 and C/EBPa are both expressed in myeloid progenitor cells we
asked the questions, How do cells differentiate into a specific lineage? and
Is there a direct interaction or cross talk between these two major
transcription factor?
To address this question we used a minimal TK promoter with
multimerized PU.1 binding sites [p(PU.1)4TK] only. This minimal
promoter was transactivated six fold upon transfection of 293T cells with
an expression plasmid of PU.1. The reporter gene expression was
determined 24 hrs after transfection. Cotransfection of a C/EBPa express
ion plasmid in the same experiment resulted in a four fold decrease of
PU.1´s transactivation capacity (Fig. 2A). As a control, co-transfection of
PU.1 and C/EBPa did not affect the activity of a minimal TK promoter
with mutated PU.1 binding sites. In further control experiments we
transfected 293T cells with a reporter construct of TK promoter with
multimerized C/EBP binding sites and a C/EBPa expression plasmid,
transactivating the promoter by 11 fold. There was no change in protein
expression of PU.1 upon co-transfection with the C/EBPa expression
plasmid as observed by western blot for PU.1 from transfected 293T cells,
ensuring that both the proteins expressed in transfected 293T cells. To
check if C/EBPa downregulates a transcription factor in a non-specific
fashion, we transfected 293T cells with expression plasmids of Gal4-
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VP16, C/EBPa  and the reporter construct Gal4-luc. Gal4-VP16
transactivates Gal4-luc by 10 folds. C/EBPa does not downregulate the
transcriptional activation of Gal4-VP16 in a non-specific fashion under
the same conditions.
4.2  C/EBPa physically interacts with PU.1
To find out whether there is a direct protein-protein interaction
between C/EBPa  and PU.1, we used GST purified GST-PU.1 and
incubated it with in vitro translated C/EBPa. An interaction between PU.1
and C/EBPa was observed. This interaction was resistant to the effect of
chaotropic agents like DTT and a change in ionic strength during the
incubation reaction (Fig. 2B ). Even in the lowest concentration of
C/EBPa, we observed an interaction of C/EBPa and PU.1. C/EBPa did
not bind to GST or the beads alone. Given the observed interaction
between C/EBPa and PU.1, the intranuclear location of these proteins was
examined. U937 cells were cytocentrifuged and labeled with PU.1 and/or
C/EBPa antibodies, respectively. The secondary antibodies were Texas
red for PU.1 and Cy-3 (green) for C/EBPa. A diffuse nuclear staining was
observed. The overlay shows that both proteins co-localize in the nucleus
(yellow) (Fig. 3). Immuno-localization studies point to a strong interaction
between PU.1 and C/EBPa.
4.3  C/EBPa inhibits c-Jun co-activation of PU.1
To understand the molecular significance of the interaction between
PU.1 and C/EBPa, and in addition, to understand if the co-activator of
PU.1, c-Jun, has any role in the interaction of PU.1 and C/EBPa, we used
F9 cells and performed transient transfections with expression plasmids of
PU.1, C/EBPa  and c-Jun. Using a minimal promoter TK with
multimerized PU.1 binding sites only [p(PU.1)4TK], we observed that
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PU.1 transactivated p(PU.1)4TK by six fold in F9 cells (Fig. 4A). F9 cells
do not express c-Jun (c-Jun expression was checked by Real time
polymerase chain reaction). When cotransfected with the expression
plasmids of c-Jun and PU.1 a strong synergistic transactivation of around
40 fold as described before was observed152. Co-transfection of C/EBPa
in the same experiment totally blocked PU.1´s transactivation capacity of
the p(PU.1)4TK promoter and also the co-activation of PU.1 by c-Jun
(Fig. 4A). As a control, F9 cells were transfected with expression
plasmids of Gal4-VP16, C/EBPa, and reporter construct Gal4-luciferase,
similar to the previously stated experiment. C/EBPa  does not
downregulate the transactivation of Gal4-VP16 in a non-specific fashion
under the same conditions.
4.4  C/EBPa displaces c-Jun from binding to PU.1 in vitro
As shown above C/EBPa inhibits c-Jun co-activation of PU.1, c-jun
has been shown to interact strongly with PU.1. We observed C/EBPa´s
interaction with PU.1. To answer the question: What is the role of c-Jun in
the context of the protein-protein interaction between C/EBPa and PU.1
complex, we performed GST pull down experiments; 35S-labelled in vitro
translated c-Jun and C/EBPa were incubated with GST-PU.1. c-Jun
strongly binds to PU.1 and C/EBPa also binds to PU.1 strongly, but when
both factors were incubated with PU.1, C/EBPa competed with c-Jun for
the binding to PU.1 (Fig. 4B). This result suggest that C/EBPa and c-Jun
interact with PU.1 through the same domain. It was shown earlier152 that
c-Jun binds to the b3-b4 region of PU.1, therefore we checked if C/EBPa
also interacted with PU.1 in the b3-b4 region of the DNA binding domain.
This was indeed the case (Fig. 4C). C/EBPd has been shown to interact
with PU.1 via its DNA binding domain. Due to a very high sequence
similarity of C/EBPa and C/EBPd, we would expect that DNA binding
domain of C/EBPa interacts with PU.1 (Fig. 4D).. Indeed, incubation of
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35S-labelled in vitro translated PU.1 with the GST-DNA binding domain
of C/EBPab showed that C/EBPa  interacts with PU.1 via its DNA
binding domain (Fig. 4D).
4.5  C/EBPa interacts with PU.1 via its leucine zipper in the
DNA binding domain
To answer the question if both the proteins interact in vivo, we
transfected 293T cells with expression plasmids of PU.1, C/EBPa ,
C/EBPaDLZ and C/EBPamBR using lipofectamine. The use of mutants
of C/EBPa in the DNA binding domain would further narrow down the
region in the DNA binding domain responsible for interaction with PU.1.
Whole cell lysates were immunoprecipitated with either rabbit-IgG or
rabbit anti-PU.1 polyclonal antibody. C/EBPa was detected by western
blotting with C/EBPa  rabbit polyclonal antibody only in PU.1
immunoprecipitates (Fig. 5A). In the control IgG immunoprecipitate no
C/EBPa  was detected. The blot was stripped and blotted for PU.1
expression (Fig. 5B). Expression of C/EBPa and its mutants were checked
by western blotting for C/EBPa (Fig. 5C). C/EBPa could not interact
with PU.1 when the leucine zipper in its DNA binding domain was
deleted, suggesting that C/EBPa interacts with PU.1 via its leucine zipper
in the DNA binding domain. This interaction of C/EBPa with PU.1 is
similar to that of C/EBPd, because C/EBPd also interacts with PU.1 via its
leucine zipper in the DNA binding domain. This shows the conservation
of interaction domains between different transcription factors of the same
family, in this case C/EBPa and C/EBPd of the C/EBP family.
To address the question of whether C/EBPa can interact with the
activation domain of PU.1, 293T cells were transfected with a Gal4-
luciferase reporter construct containing a minimal promoter with Gal4
DNA binding sites only, and expression plasmids of C/EBPa and PU.1
activation domain fused to the DNA binding domain of Gal4 (PU.1-Gal4).
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PU.1-Gal4 transactivates the Gal4-luciferase reporter 4.5 fold and this
transactivation was blocked by C/EBPa , C/EBPa  does not non-
specifically inhibit the transactivation of Gal4-VP16 in transactivating
Gal4-luc reporter construct. These results indicate atleast more than one
functional interaction of C/EBPa with PU.1; further investigations are
required to define the interaction of C/EBPa with the activation domain of
PU.1. However, there are alternative interpretations for the above data
e.g., C/EBPa  could quench more of the co-activators (CBP/p300)
recruited by PU.1 activation domain and thereby a decrease in the
transactivation capacity of PU.1 when co-transfected with C/EBPa (Fig.
6) without physically interacting with PU.1.
4.6  C/EBPa does not recruit TSA-sensitive co-repressors in
downregulating PU.1´s transcriptional activity
To investigate whether C/EBPa is recruiting co-repressors to down-
regulate PU.1´s transactivation capacity, we transfected F9 cells with the
TK promoter containing PU.1 binding sites and expression plasmids of
PU.1, and C/EBPa. We found that C/EBPa blocks the activity of PU.1
transactivating the minimal TK promoter with PU.1 binding sites.
Trichostatin A (TSA) was shown to be an inhibitor of a class of co-
repressors. The transcription factor ETV6 (Tel) recruits these co-
repressors and represses the promoter activity of Gal4-luciferase. Addition
of TSA releases this repression as it is seen in the transfection of 293T
cells with Gal4-Tel. In a similar experiment where the transactivation
block of PU.1 by C/EBPa is seen, addition of TSA did not release the
repression. These data suggest that repression of PU.1´s activity by
C/EBPa  is not mediated by the recruitment of TSA-sensitive co-
repressors (Fig. 7).
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4.7  C/EBPa downregulates PU.1 expression in myeloid U937
cells
We investigated if C/EBPa blocks the expression of PU.1 target
genes. As PU.1 is autoregulatory in its expression113, PU.1 itself is a target
gene of PU.1. We therefore performed quantitative real time PCR using
Real time Light Cycler technology (Roche) to determine the expression of
PU.1 gene in the U937 cell line with Zn-inducible expression of
C/EBPa153. Ectopic expression of C/EBPa in U937 bipotential myeloid
cells resulted in differentiation of cells towards the neutrophil lineage.
Induction of C/EBPa expression upon stimulation with Zn was observed
by western blot analysis for C/EBPa. To correct for the variances in the
cDNA synthesis step, PU.1 expression was set in relation to the G6PD
housekeeping gene by calculating the ratios for PU.1/G6PD. C/EBPa was
expressed maximally after 6 hrs of Zn induction, and five time points of
zinc induction were included to check for PU.1 expression. PU.1
expression was downregulated four fold after 8 hrs. In the control there
was only a minimal change in PU.1 expression upon induction with zinc
in U937 cells carrying the empty vector pPC18 (Fig. 8A). The data are
consistent with the model that expression of PU.1 is downregulated after
blocking of PU.1 function by C/EBPa. We extrapolated this observation
to promoter studies. 293T cells were transfected with human PU.1
promoter with luciferase activity and expression plasmids of PU.1 and
C/EBPa. PU.1 transactivated the promoter by about 5 folds. C/EBPa
alone transactivated the promoter by 2 folds. pGL2 was used as a control.
C/EBPa blocked the transactivation of PU.1 promoter by PU.1 (Fig. 8B).
4.8  C/EBPa inhibits PU.1 induced dendritic cell development
It was previously shown that the enforced expression of C/EBPa in
a human bipotential myeloid progenitor cell line induces granulocytic
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differentiation and blocks monocytic differentiation153. On the other hand,
PU.1 has been demonstrated to instruct transformed chicken multipotent
hematopoietic progenitors to differentiate along the myeloid lineage8. In
human CD34+ hematopoietic progenitor cells, however, enforced
expression of PU.1 promotes dendritic cell differentiation with
characteristics of Langerhans cells, specified dendritic cells that reside in
the epidermis154. To investigate biological significance of function
blocking of PU.1 by C/EBPa, we retrovirally expressed PU.1 and C/EBPa
in human CD34+ hematopoietic progenitor cells. In contrast to mock
control in which both granulocytic and monocytic cells differentiated (Fig.
9A), single transduction of PU.1 and C/EBPa predominantly promoted
differentiation of CD1a+ dendritic cells (Figs. 9B ,E and F ) and
granulocytes (Fig. 9C), respectively. PU.1 transduced cells were positive
for CD1a, HLA-DR, CD80 and CD86 (Fig. 9F) suggesting that PU.1
specifically enhanced the dendritic cell expression.  In the latter case of
C/EBPa transduction, terminal differentiation of neutrophils was markedly
enhanced compared to mock control. Lineage specific differentiation
markers were observed by FACS analysis of the surface antigens CD14
and CD15. Then, we coexpressed PU.1 and C/EBPa  in CD34+
hematopoietic progenitor cells. In accordance with our mechanistic data of
C/EBPa  blocking PU.1´s transcriptional activity, C/EBPa  blocked
dendritic cell differentiation by PU.1, and instead induced granulocytic
differentiation (Fig. 9D and E).
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5  DISCUSSION
According to the current view of hematopoiesis, all blood cell types
derive from a common pluripotent stem cell. In the adult organism the
stem cells are found in the bone marrow where they divide to produce
more stem cells (self renewal) and various progenitor cells committed to a
single lineage which terminally differentiate to morphologically and
functionally distinct erythroid, myeloid, or lymphoid cells. Within the
myeloid compartment the same committed precursor can give rise to
monocytic or granulocytic cells. This raises a question: What are the
molecular mechanisms that dictate the fate of the common precursor to
one or the other of these two diverse myeloid lineages?
 The two transcription factors PU.1 and C/EBPa play a major role in
myelopoiesis. Both factors have been shown to synergize on various
promoters including M-CSF receptor promoter and neutrophil elastase
promoter. Both factors are expressed in bipotential myeloid cell, and
therefore we were interested in knowing if there is any protein-protein
interaction between these transcription factors and consequently if there is
any functional significance of this interaction in lineage commitment.
Although it was shown earlier that PU.1 and C/EBPa synergize on
promoters with both PU.1 and C/EBPa binding sites like the M-CSF, G-
CSF and GM-CSF receptor promoters, it had not been reported that
C/EBPa can block or downregulate the promoter activity of PU.1. The
present work shows that the transcription factor C/EBPa is capable of
functionally blocking PU.1 ability to transactivate a promoter with PU.1
binding sites. C/EBPa blocked PU.1 ability to transactivate the M-CSF
receptor promoter with PU.1 binding sites alone. We also investigated if
there are any protein-protein interaction between PU.1 and C/EBPa. Our
results show that there is indeed an interaction between the two proteins
and the interaction sites responsible for this interaction were mapped: the
leucine zipper in the DNA binding domain of C/EBPa interacts with the
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b3-b4 region of the DNA binding domain of PU.1. Various studies have
reported that the transcription factors GATA-1, C/EBPd, c-Jun and AML-
1 interact with this b3-b4 domain of PU.1. It has previously been shown
that the transcription factor c-Jun is a JNK independent co-activator of
PU.1, physically interacting with PU.1 in the b3-b4 region resulting in an
increased M-CSF receptor expression. We show that as a consequence of
the interaction of C/EBPa with PU.1 in the b3-b4 region the co-activator
c-Jun is displaced from binding to PU.1 and PU.1 function is inhibited.
Investigating further the role of C/EBPa as a regulatory switch in
hematopoietic cells, we used the bipotential U937 cells where it was
shown that enforced expression of C/EBPa differentiates the cells along
the granulocytic lineage153. Furthermore the induction of the granulocytic
pathway results in up-regulation of C/EBPa . We investigated the
expression of the monocytic specific factor PU.1 upon induction of U937
cells towards granulocytic lineage i.e., we looked for PU.1 expression in
U937 cells with conditional ectopic expression of C/EBPa. PU.1 is auto-
regulatory in its expression in myeloid cells. We observed that C/EBPa
down-regulates PU.1 expression upon conditional ectopic induction of
C/EBPa. It was further shown that C/EBPa blocks PU.1 transactivation of
the human PU.1 promoter. Our data suggest that C/EBPa might block
PU.1 transactivation capacity and thereby the ability of PU.1 to increase its
own expression. It is interesting to note that a similar phenomenon of
inhibiting PU.1 activity was observed with the transcription factor GATA-
1. GATA-1 is capable of suppressing the myeloid phenotype without
interfering with PU.1 gene expression, but instead was capable of
inhibiting the activity of the PU.1 protein in a dose-dependent manner155.
This inhibition was independent of the ability of GATA-1 to bind DNA,
suggesting that it is mediated by protein-protein interaction. PU.1 interacts
with GATA via PU.1 ETS domain. A similar interaction has been shown
with a C/EBP family member C/EBPd: C/EBPd interacts with PU.1 via
the leucine zipper of the DNA binding domain. This region of C/EBP
interacting with PU.1 might be of great importance for the commitment of
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cells to granulocytes. It should further be noted that mutations have been
detected in the DNA binding domain of C/EBPa  in acute myeloid
leukemia separately by two different groups40, suggesting its importance in
lineage commitment to granulocytes and in leukemia.
Repression of transcriptional activity by transcription factors has
been attributed to the recruitment of co-repressors. Transcriptional
repressors interacting with transcription factors reduce or repress the
transactivation capacity. To rule out the possibility of such a phenomenon;
i.e. C/EBPa recruiting co-repressors to PU.1 and blocking its function, we
used a repressor inhibitor to release the repression by C/EBPa .
Trichostatin A (TSA) is a HDAC inhibitor and it releases repression
induced by HDAC’s. In transient transfection assays C/EBPa blocked
PU.1´s activity even in the presence of TSA, suggesting that there are no
co-repressors involved in blocking PU.1´s function by C/EBPa.
It has previously been shown that PU.1 is important and essential
for the development of monocytes. DeKoter et al. have also shown that
the activation domain of PU.1 is essential to drive the cells to monocytes.
We observed that C/EBPa is functionally interacting with the activation
domain of PU.1. Further investigation on this interaction and its possible
role in lineage commitment is required. Interaction of C/EBPa with the
activation domain of PU.1 might disrupt possible protein-protein
interactions, important for the PU.1 induced differentiation program. One
of the candidates is CBP/p300, a co-activator of PU.1, which binds to the
transactivation domain of PU.1. Inhibition of such an interaction by
C / E B P a  would further block PU.1´s activity to induce
monocytes/dendritic cells and enhance C/EBPa´s capacity to induce
granulocytes. One could then speculate that C/EBPa might compete with
the co-activator p300/CBP for binding to PU.1 thereby reducing the
transactivation capacity of PU.1.
With regard to the instructive ability of C/EBP transcription factors
to drive granulocytic differentiation, most of the evidence has been based
on the experiments using cell lines. It has been shown earlier that the
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C/EBPa gene is activated at the stage of myeloid commitment and is
specifically expressed in granulocytic cells. Increased levels of C/EBPa
expressed from an inducible promoter construct directed differentiation
along the granulocytic pathway, as determined by morphological criteria.
These data suggest the role of C/EBPa as a molecular switch during early
hematopoietic developmental events that direct cells to the granulocytic
pathway. C/EBPa blocked monocytic differentiation of these human
bipotential myeloid progenitor cells. During TPA stimulation of
monocytic development endogenous C/EBPa was down-regulated and
this down-regulation is required for differentiation along the monocytic
pathway153. Ectopic expression of C/EBPa represses PU.1 expression in
bi-potential U937 myeloid cells.
To prove the biological meanings of the functional inhibition of
PU.1 by C/EBPa, CD34+ hematopoietic progenitor cells were transduced
with PU.1 and/or C/EBPa. We present here the first evidence that the
C/EBPa transcription factor drives the granulocytic differentiation of
primary hematopoietic cells. CD34+ cells transduced with C/EBPa
preferentially developed eosinophills. C/EBP transcription factors have
been implicated in the development of eosinophills in cooperation with
GATA-1. Our data suggest that C/EBP overload is enough to drive
eosinophilic commitment of myeloid progenitor cells. Neutrophilic
differentiation and maturation is markedly enhanced with wild type
C/EBP. This finding confirms the previous observation that enforced
expression of C/EBPa in a bipotential human myeloid cell line promotes
neutrophilic differentiation. PU.1 is expressed throughout the myeloid
lineage and is a master regulator involved in the development and function
of all myeloid progenies. On the other hand, C/EBP family transcription
factors have been shown to cooperate with PU.1 in transactivating
promoters specific to granulocytes and/or macrophages. CD34+ cells
transduced with PU.1 promoted dendritic cell (DC) development. Mice
with targeted disruption of the PU.1 gene reportedly lack the major
population of myeloid DCs. DC development induced by PU.1 imitates
55
that induced by TNFa. TNFa activates c-Jun N-terminal kinase which
then phosphorylates and activates c-Jun, a PU.1 co-activator. Thus, it is
possible that the downstream target of TNFa is PU.1 in terms of induction
of DC development. In this context, C/EBP might act as a negative
regulator by displacing c-Jun from binding to PU.1. Another possibility is
that NFkB activated by TNFa cooperates with PU.1.
PU.1 and C/EBP binding sites are located in close proximity on
most of the promoters specific to granulocytes and/or macrophages and
these two factors synergistically transactivate these promoters. On the
other hand, we show here that C/EBPa physically interacts with PU.1 on
the promoter with PU.1 binding site only, and displaces c-Jun, a co-
activator of PU.1 from binding to PU.1, resulting in the suppression of
PU.1 transactivation. We expect this kind of interaction to happen during
commitment of pluripotent myeloid progenitor cells.  PU.1 drives
dendritic cell development while C/EBPa  direct cells towards
granulocytes. In accordance with our model, when the cells were co-
transduced with PU.1 and C/EBPa, C/EBPa  inhibited PU.1-induced
dendritic cell lineage commitment. Myeloid progenitors in the CD34+ cell
fraction are mostly pluripotent in their differentiation potential and can
give rise to bipotential granulocyte/macrophage progenitors, eosinophils
and Langerhans cells. Our biological data demonstrate that C/EBPa
blocks PU.1-induced dendritic cell commitment in pluripotent myeloid
progenitors. Altogether, our data indicate that C/EBPa drives granulocytic
differentiation of myeloid progenitors by suppressing myeloid derived
dendritic cell differentiation by blocking PU.1 function. DCs are major
target cells for therapeutic approaches to allergy, autoimmune disease,
infectious disease, and cancer. We propose that modulating transcription
factors in myeloid progenitor cells would be a new approach to
manipulate DC development and effector functions in vivo. Our approach
will provide useful information to therapeutic manipulation of the immune
system (Figure 10).
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In conclusion these results demonstrate a novel mechanism by which
function of a lineage-specific transcription factor is inhibited by another
lineage-restricted factor through direct protein-protein interactions. These
findings not only contribute to understand the mechanisms involved in
lineage commitment but also throw light on how protein-protein
interactions participate in hematopoietic differentiation and leukemo-
genesis.
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6  Summary
Several transcription factors have been shown to play a role in
myelopoiesis. PU.1, an ets-family transcription factor, is required for the
development of both myeloid and lymphoid lineages while the
transcription factor CCAAT/enhancer binding protein family member
C/EBPa is essential for granulocytic development. We present here the
first evidence that C/EBPa blocks the function of PU.1. PU.1 and C/EBPa
interact physically and co-localize in myeloid cells. As a consequence of
this interaction C/EBPa can inhibit the function of PU.1 to activate a
minimal promoter containing only PU.1 DNA binding sites. We further
demonstrate that the leucine zipper in the DNA binding domain of
C/EBPa interacts with the b3/b4 region in the DNA binding domain of
PU.1, and as a result displaces the PU.1 co-activator c-Jun. Finally,
C/EBPa blocks PU.1 induced dendritic cell development from CD34+
human cord blood cells. The functional blocking of PU.1 by C/EBPa
could be the mechanism by which C/EBPa inhibits the cell fates specified
by PU.1, and directs cell development to the granulocytic lineage.
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Zussamenfassung
Verschiedene Transkriptionsfaktoren spielen eine Rolle in der
Entwicklung myeloischer Zellen. PU.1, ein Transkriptionsfaktor aus der
ETS-Familie, ist sowohl für die Entwicklung lymphatischer als auch für
die Entwicklung myeloischer Zellen von Bedeutung. Der Transkriptions
faktor C/EBPa, ein an den CCAAT-Enhancer bindendes Protein, ist
hingegen wesentlich verantwortlich für die Entwicklung von
Granulozyten. Wir stellen hier den ersten Nachweis dafür vor, dass
C/EBPa die Funktion von PU.1 blockiert. PU.1 und C/EBPa können
einander binden und sind in myeloischen Zellen kolokalisiert. Wenn
C/EBPa  PU.1 bindet, kann PU.1 einen minimalen Promotor mit
Bindungsstelle für PU.1 nicht mehr aktivieren. Wir zeigen, dass der
Leuzin-Zipper in der DNA-bindenden Domäne von C/EBPa mit der
b3/b4-Region in der DNA-bindenden Domäne von PU.1 interagieren
kann. Dadurch wird der Koaktivator von PU.1, c-jun, aus seiner Bindung
mit PU.1 verdrängt. C/EBPa hemmt PU.1 nicht, indem es Korepressoren
rekrutiert. Vielmehr vermindert C/EBPa die Expression von PU.1 in U-
937-Zellen mit induzierbarem C/EBPa, indem es den autoregulatorischen
Effekt PU.1 auf den PU.1-Promotor hemmt.
Ausserdem blockiert C/EBPa die durch PU.1 bedingte Entwicklung
dendritischer Zellen aus CD34+ menschlichen Nabel blutzellen. Diese
funktionelle Blockade von PU.1 durch C/EBPa  könnte einer der
Mechanismen sein, mit denen C/EBPa den durch PU.1 determinierten
Weg der Zelldifferenzierung hemmt und sich Zellen unter dem Einfluss
von C/EBPa zu Granulozyten entwickeln.
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